Drugs like bevacizumab and sorafenib are able to slow tumor progression by interfering with the vascular endothelial growth factor (VEGF) and its receptor, VEGFR2, although these and other anti‐VEGF therapies have often shown limited efficacy in long‐term treatments due to acquired resistance and toxicities.6, 7, 8, 9. The gene discussed is KDR; the disease is neoplasm.